August 14, 2013 -- Mucosis B.V., a clinical-stage Dutch biotechnology company, announced the publication on Monday of preclinical data demonstrating that its SynGEM intranasal respiratory syncytial virus vaccine is safe and protective in animal models.
The report, which was published in PLoS ONE, showed that SynGEM induced locally secreted immunoglobulin A antibodies in the mucosal layers and robust levels of systemic virus neutralizing antibodies in mice and cotton rats. SynGEM is a vaccine based on Mucosis’ Mimopath vaccine technology which enables the presentation of a stable prefusion-like trimeric F protein. The trimeric F protein is considered important for the induction of functional immunity.
Read the rest of the article here.